CoChat
Sign Up
Cited by 163Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., Martinez-Marti, A., Tufman, A., Lambrecht, M., Andratschke, N., Piguet, A.C., Kassapian, M., Roschitzki-Voser, H., Rabaglio-Poretti, M., Stahel, R.A., Vansteenkiste, J., De Ruysscher, D.·2019·Lung Cancer
DOI 10.1016/j.lungcan.2019.05.001
Open this paper in CoChat — free account

Abstract

Objectives Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in pre-clinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.Material and methods NICOLAS is a phase-II trial evaluating the safety and efficacy of nivolumab combined with CRT in stage III NSCLC. Patients received 3 cycles of platinum-based chemotherapy and concurrent RT (66 Gy/33fractions). Nivolumab started concurrently with RT. The primary endpoint was 6-month post-RT rate of grade-≥3-pneumonitis. A formal interim safety analysis (IA) was scheduled when the first 21 patients reached 3 months follow-up post-RT. An early positive safety conclusion would be reached at IA if there were no grade ≥3-pneumonitis in those patients. Efficacy evaluation was planned provided the safety conclusion was reached.Results and conclusion As of 13 December 2018, 82 patients were recruited with median follow-up of 13.4 months. The most frequent adverse events (AEs) were anaemia, fatigue and pneumonitis. No unexpected AEs or increased toxicities were observed. For the first 21 patients, no grade-≥3-pneumonitis was observed by the end of the 3-month post-RT follow-up period. The early safety IA provides evidence that the addition of nivolumab to concurrent CRT is safe and tolerable regarding the 6-month rate of pneumonitis grade ≥3 at the one-sided significance level of 5%. Following that, the 1-year progression-free survival will be evaluated in an expanded patient cohort. NICOLAS trial creates the opportunity for assessing the activity of the combination of checkpoint with concurrent CRT in larger prospective trials for locally advanced NSCLC.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2019.05.001

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 163

Related

See all

Metadata

Authors
Peters, S., Felip, E., Dafni, U., Belka, C., Guckenberger, M., Irigoyen, A., Nadal, E., Becker, A., Vees, H., Pless, M., Martinez-Marti, A., Tufman, A., Lambrecht, M., Andratschke, N., Piguet, A. C., Kassapian, M., Roschitzki-Voser, H., Rabaglio-Poretti, M., Stahel, R. A., Vansteenkiste, J., & De Ruysscher, D.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Vall d'Hebron Hospital Universitari (ES)
  • National and Kapodistrian University of Athens (GR)
  • LMU Klinikum (DE)
  • Hospital Virgen de la Salud (ES)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Klinik Hirslanden (CH)
  • Kantonsspital Winterthur (CH)
  • German Center for Lung Research (DE)
  • Universitair Ziekenhuis Leuven (BE)
  • University of Zurich (CH)
  • European Thoracic Oncology Platform (CZ)
  • Frontier Science Foundation-Hellas (GR)
  • University Hospital Zurich (CH)
ORCID
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2019-07
Volume
133
Pages
83-87
ISSN
0169-5002 (ISSN-L)
DOI
10.1016/j.lungcan.2019.05.001
OpenAlex
W2943437728
Cited by
162
References
12
Citations by year
2026: 8 · 2025: 22 · 2024: 19 · 2023: 18 · 2022: 24 · 2021: 33 · 2020: 35 · 2019: 3
FWCI
17.44
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • IRIS (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • ETOP
  • Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
nivolumab, concurrent chemoradiotherapy, non-small cell lung cancer, stage III NSCLC, anti-PD-1 therapy, PD-L1 blockade, pneumonitis, treatment safety, platinum-based chemotherapy, immune checkpoint inhibitors, locally advanced non-small cell lung cancer
MeSH terms
Nivolumab, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Cohort Studies, Survival Analysis, Treatment Outcome, Platinum Compounds, Chemoradiotherapy, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review